Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer

Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer

Purpose: CDK4/6 inhibitors (CDK4/6i) use has revolutionized the treatment of hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer. The choice of a specific CDK4/6i may be influenced by adverse events (AEs). Recently, the Italian Medicines A...

Full description

Saved in:
Bibliographic Details
Main Authors: Paola Zagami, Angela Esposito, Beatrice Taurelli Salimbeni, Pier Paolo Maria Berton Giachetti, Roberta Scafetta, Matteo Lambertini, Massimo Di Maio, Giuseppe Curigliano, Carmen Criscitiello, Saverio Cinieri
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Breast
Subjects:
Breast cancer
CDK4-6i
Metastatic treatment and endocrine-based therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977625000049
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items